Register to the NASH Club and join our experts!

Prof. Gianluca Perseghin

Prof. Jeffrey Lazarus

Prof. Laurent Castéra

Prof. Massimo Pinzani

Prof. Cyrielle Caussy

Dr. Rachel Pryke

Prof. Jörn Schattenberg

Prof. Jose Luis Calleja

Prof. Wolf Peter Hofmann

Prof. Manuel Romero Gomez

Prof. Philip Newsome

Prof. Salvatore Petta
AGENDA
COURSE DESCRIPTION
CME CREDITS
AGENDA
PAST EPISODES
EPISODE 1
NAFLD-NASH Epidemiology, diagnostic tools and strategies
Tuesday, 7th March 2023 ► 7pm – 8pm (GMT+1)
EPISODE 2
Creating referral pathways for the NAFLD/NASH patients beyond the liver clinic
Tuesday, 4th April 2023 ► 7pm – 8:15pm (GMT+2)
EPISODE 3
NASH: Current and future treatment options
Thursday, 4th May 2023 ► 7pm – 8pm (GMT+2)
COURSE DESCRIPTION
2 million deaths per year worldwide are caused by Chronic Liver Disease (CLD). Globally, the most common cause of CLD is Non-Alcoholic Fatty Liver Disease (NAFLD) which is estimated to affect approximately 25% of the world population. 73% of patients with type 2 diabetes mellitus have NAFLD. Non-Alcoholic Steatohepatitis (NASH), a progressive form of NAFLD which combines fatty liver, liver inflammation and liver damage, is the 2nd most common aetiology of hepatocellular (HCC) requiring liver transplantation.
Join the 2023 NASH Club, a series of 3 full educational CME accredited interactive and hybrid event dedicated to all matters NAFLD-NASH. You will learn from 12 top experts from a wide range of medical specialties: Hepatologists, Diabetologists, Endocrinologists, General practitioners and Gastroenterologists coming from different EU countries.
Overall Learning Objectives
- Learn more about the importance of liver diseases early screening, including in primary point of care and the latest available tools and techniques to perform liver exams.
- Closing the loop: Understand how coordination between medical specialties can help optimize patient journey and care.
- Get to know current NAFLD-NASH treatment and future NASH treatment options including drugs in phase 3.
CME CREDITS
This programme is accredited by EBAC for 3 hours of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity
In compliance with EBAC guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
After completing the 3-part course, you will receive an email with instructions to receive your CME credits. If you do not receive this email, please contact t.avice@comnco.com.


NAFLD-NASH Epidemiology, diagnostic tools and strategies
Chair: Prof. Massimo Pinzani
Speakers: Prof. Jeffrey Lazarus, Prof. Laurent Castéra & Prof. Gianluca Perseghin

Prof. Massimo Pinzani

Prof. Jeffrey Lazarus

Prof. Laurent Castéra

Prof. Gianluca Perseghin
SESSION AGENDA
Chair: Prof. Massimo Pinzani
Introduction (Prof. Massimo Pinzani)
Epidemiology /public Health (Prof. Jeffrey Lazarus)
- Population impacted/ Why are patients underdiagnosed?
- Why NASH can become a big challenge for EU healthcare system?
Liver diseases diagnostics tools and strategies (Prof. Laurent Castéra)
- Tools and techniques
- Latest clinical studies and latest guidelines
NAFLD among T2D patients (Prof. Gianluca Perseghin)
Conclusion (Prof. Massimo Pinzani)

Creating referral pathways for the NAFLD/NASH patients beyond the liver clinic
Chair: Prof. Jörn Schattenberg
Speakers: Prof. Jose Luis Calleja, Prof. Cyrielle Caussy, Prof. Wolf Peter Hofmann & Dr. Rachel Pryke

Prof. Jörn Schattenberg

Prof. Jose Luis Calleja

Prof. Cyrielle Caussy

Prof. Wolf Peter Hofmann

Dr. Rachel Pryke
SESSION AGENDA
Chair: Prof. Jörn Schattenberg
Introduction (Prof. Jörn Schattenberg)
Role of primary care or GP in early screening and referral of NAFLD patients (Prof. Jose Luis Calleja, Dr. Rachel Pryke)
Role of diabetologists/endocrinologists in screening NAFLD/NASH among T2D patients and patients with cardio metabolic disease: epidemiology, clinical studies and guidelines (Prof. Cyrielle Caussy)
Roundtable: Multidisciplinary approach in practice (Prof. Wolf Peter Hofmann, Dr. Rachel Pryke, Prof. Cyrielle Caussy, Prof. Jose Luis Calleja)
Conclusion (Prof. Jörn Schattenberg)

NASH: Current and future treatment options
Chair: Prof. Salvatore Petta
Speakers: Prof. Manuel Romero Gomez & Prof. Philip Newsome

Prof. Salvatore Petta

Prof. Manuel Romero Gomez

Prof. Philip Newsome
SESSION AGENDA
Chair: Prof. Salvatore Petta
Introduction (Prof. Salvatore Petta)
Impact of lifestyle change: diet and exercise (Prof. Manuel Romero Gomez)
Treating comorbidities (Prof. Romero-Gomez)
Future treatment drugs in stage 3 (Prof. Philip Newsome)
Conclusion (Prof. Salvatore Petta)